[February 15, 2018]

Vectibix (panitumumab; Amgen/Takeda) Drug Analysis 2018 - ResearchAndMarkets.com

The "Drug analysis: Vectibix" drug pipelines has been added to ResearchAndMarkets.com's offering.

Drug Overview

Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 (News - Alert) monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents the activation of EGFR and halts the cascade of intracellular signals dependent on this receptor. Preclinical studies have shown that Vectibix results in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.

Product Profles

List of Figures

Figure 1: Vectibix for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Vectibix for colorectal cancer

Figure 3: Drug assessment summary of Vectibix for colorectal cancer

Figure 4: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables

Table 1: Vectibix drug profile

Table 2: Overview of major approvals for Vectibix in colorectal cancer

Table 3: Vectibix pivotal trial data in colorectal cancer

Table 4: Vectibix early-phase data in colorectal cancer

Table 5: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 6: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016-25

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pgjplg/vectibix?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006104/en/

[ Back To TMCnet.com's Homepage ]